EyePoint to Cut Workforce 53% After Experimental Drug Fails Trial
EyePoint said it would cut about 53% of its workforce and stop studies of its experimental drug for an age-related vision disease after the drug failed a second late-stage trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.